Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 Oct;49(10):4180-4.
doi: 10.1128/AAC.49.10.4180-4184.2005.

Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002

Affiliations
Comparative Study

Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002

M Rantala et al. Antimicrob Agents Chemother. 2005 Oct.

Abstract

The prevalence and mechanisms of macrolide resistance among 1,007 clinical pneumococcal isolates collected in Finland were investigated. Of these, 217 (21.5%) were resistant to erythromycin and 11% to clindamycin. Among the erythromycin-resistant isolates, mef(E) was present in 95 isolates (44%), mef(A) was present in 12 isolates (6%), and erm(B) was present in 90 isolates (41%). A double mechanism, mef(E) and erm(B), was detected in five isolates (2%). Ribosomal mutation was detected in 14 (6%) macrolide-resistant isolates in which no other determinant was found. Based on the telithromycin MICs, two groups of isolates were formed: 83.3% of the isolates belonged to a major group for which the telithromycin MIC range was < or =0.008 to 0.063 microg/ml, and 16.7% belonged to a minor group for which the telithromycin MIC range was 0.125 to 8 microg/ml. All except three isolates in the minor population carried a macrolide resistance gene.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Distribution of telithromycin MICs of macrolide-susceptible and -resistant pneumococci harboring a macrolide resistance mechanism. Of the susceptible pneumococci, 41 isolates were randomly tested for the presence of a macrolide resistance determinant; none of them carried any macrolide resistance mechanism. Bars with slashes, isolates susceptible to erythromycin and azithromycin (n = 787); gray bars, isolates with mutations or undetermined mechanism (n = 17); spotted bars, isolates with mef(A) or mef(E) (n = 107); black bars, isolates with erm(B) or erm(TR) (n = 91); white bars, isolates with double mechanism erm(B) and mef(E) (n = 5).

Similar articles

Cited by

References

    1. Ackermann, G., and A. C. Rodloff. 2003. Drugs of the 21st century: telithromycin (HMR 3647)—the first ketolide. J. Antimicrob. Chemother. 51:497-511. - PubMed
    1. Amezaga, M. R., P. E. Carter, P. Cash, and H. McKenzie. 2002. Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites. J. Clin. Microbiol. 40:3313-3318. - PMC - PubMed
    1. Bean, D. C., and J. D. Klena. 2002. Prevalence of erm(A) and mef(B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand. J. Antimicrob. Chemother. 50:597-599. - PubMed
    1. Canu, A., B. Malbruny, M. Coquemont, T. A. Davies, P. C. Appelbaum, and R. Leclercq. 2002. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46:125-131. - PMC - PubMed
    1. Daly, M. M., S. Doktor, R. Flamm, and D. Shortridge. 2004. Characterization and prevalence of MefA, MefE, and the associated msr(D) gene in Streptococcus pneumoniae clinical isolates. J. Clin. Microbiol. 42:3570-3574. - PMC - PubMed

Publication types

MeSH terms